|
Market Closed -
Nasdaq
00:00:00 10/11/2026 +03
|
After hours 03:59:58 | |||
| 269.00 USD | +5.83% |
|
270.80 | +0.67% |
| 11-09 | Goldman Sachs Adjusts Price Target on Moderna to $195 From $137 | MT |
| 11-09 | Piper Sandler Adjusts Price Target on Moderna to $305 From $230 | MT |
| Market Cap | 109B 97.15B 89.4B 81.14B 154B 10,202B 158B 1,069B 426B 5,462B 409B 400B 17,203B | P/E 2026 * |
-35.5x | P/E 2027 * | -60.5x |
|---|---|---|---|---|---|
| Enterprise Value | 104B 92.85B 85.44B 77.54B 147B 9,750B 151B 1,022B 407B 5,220B 390B 382B 16,441B | EV / Sales 2026 * |
43.8x | EV / Sales 2027 * | 39.8x |
| Free-Float |
92.64% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| MRNA | Delayed | |
CBOE
| MRNA | Real-time | |
|
Tradegate
| 0QF | Real-time | |
|
Xetra
| 0QF | Delayed | |
|
Borsa Italiana
| 1MRNA | End-of-day quote | |
|
CBOE
| Real-time | ||
|
Boerse Muenchen
| 0QF | Real-time | |
|
Börse Stuttgart
| 0QF | Delayed | |
|
London S.E.
| 0A45 | Delayed | |
|
Deutsche Boerse AG
| 0QF | Delayed | |
|
Mexican S.E.
| MRNA * | End-of-day quote | |
|
Wiener Boerse
| MRNA | End-of-day quote | |
|
Kazakhstan S.E.
| MRNA_KZ | End-of-day quote | |
|
Lima
| MRNAUS | End-of-day quote | |
|
CBOE
| 0A45 | Real-time | |
|
Swiss Exchange
| MRNA | Delayed | |
|
Swiss Exchange
| MRNA | Delayed |
Last Transcript: Moderna, Inc.
| 1 day | +0.67% | ||
| 1 week | +21.81% | ||
| Current month | +21.32% | ||
| 1 month | +19.56% | ||
| 3 months | +354.62% | ||
| 6 months | +394.94% | ||
| Current year | +812.17% |
| 1 week | 230.21 |  | 280.8 |
| 1 month | 179.53 | | 280.8 |
| Current year | 29.81 | | 280.8 |
| 1 year | 22.28 | | 280.8 |
| 3 years | 22.28 | | 280.8 |
| 5 years | 22.28 | | 376.65 |
| 10 years | 11.54 | | 497.49 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 54 | 01/03/2011 |
James Mock
DFI | Director of Finance/CFO | 49 | 06/09/2022 |
Stephen Hoge
PSD | President | 50 | 01/11/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Noubar Afeyan
CHM | Chairman | 63 | 01/02/2012 |
Stéphane Bancel
BRD | Director/Board Member | 54 | 01/03/2011 |
Francois Nader
BRD | Director/Board Member | 69 | 11/12/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/15/26 A | Exercice | Chairperson | 192,049 | 0.0481% | ||
| 10/5/26 A | Other | Chief Operating Officer | 125,000 | 0.0313% | ||
| 10/5/26 A | Exercice | Chief Financial Officer | 3,612 | 0.0009% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +5.83% | +21.81% | +996.17% | +286.99% | 103B | |
| +4.28% | +0.07% | +52.75% | +138.78% | 1,206B | |
| +2.13% | +4.27% | +51.21% | +91.36% | 665B | |
| +0.68% | +1.54% | +33.83% | +112.47% | 515B | |
| +2.77% | +0.98% | +49.44% | +68.46% | 381B | |
| +1.38% | +0.27% | +72.42% | +45.30% | 362B | |
| +0.29% | +1.48% | +30.84% | +58.32% | 307B | |
| +0.98% | +1.49% | +9.04% | +34.78% | 289B | |
| +1.04% | -0.05% | +45.29% | +76.18% | 249B | |
| +1.46% | -0.59% | +42.48% | +125.82% | 207B | |
| Average | +1.60% | +2.50% | +138.35% | +103.85% | 428B | |
| Weighted average by Cap. | +2.26% | +1.16% | +68.81% | +100.63% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.38B 2.12B 1.95B 1.77B 3.36B 223B 3.44B 23.35B 9.31B 119B 8.92B 8.73B 376B | 2.65B 2.37B 2.18B 1.98B 3.75B 249B 3.84B 26.06B 10.39B 133B 9.96B 9.74B 419B |
| Net income | -3.05B -2.72B -2.5B -2.27B -4.31B -286B -4.41B -29.96B -11.94B -153B -11.45B -11.2B -482B | -1.68B -1.5B -1.38B -1.26B -2.38B -158B -2.44B -16.55B -6.6B -84.52B -6.32B -6.19B -266B |
| Net Debt | -4.82B -4.3B -3.96B -3.59B -6.81B -452B -6.98B -47.36B -18.88B -242B -18.09B -17.7B -762B | -3.26B -2.91B -2.68B -2.43B -4.61B -306B -4.72B -32.03B -12.77B -164B -12.24B -11.98B -515B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/11/26 | $269.00 | +5.83% | 12,339,771 |
| 06/11/26 | $254.19 | +5.27% | 16,329,129 |
| 05/11/26 | $241.46 | -6.55% | 12,032,003 |
| 04/11/26 | $258.38 | +13.11% | 14,808,313 |
| 03/11/26 | $228.44 | +3.45% | 9,515,743 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- MRNA Stock
Select your edition
All financial news and data tailored to specific country editions
